Abstract:Introduction: Important immunotherapy drugs targeting PD-L1 are approved for first and second line treatment for various stages of NSCLC. Reproducible and precise evaluation of PD-L1 expression is essential to accurately evaluate patients' eligibility for treatment and for enrollment in clinical trials. Current guidelines rely on pathologists to interpret tumor samples, which is challenging in part because different PD-L1 assays have distinct scoring criteria. As a result, determining eligibility by manual assessment can be inconsistent and inaccurate, leading to untreated patients. To support pathologist quantification of PD-L1 in clinical trials, PathAI has developed scanner-and antibody-agnostic machine learning (ML) models, AI-based histologist measurement of PD-L1 in NSCLC (AIM-PD-L1-NSCLC), for the quantification of PD-L1 expression in NSCLC using four PD-L1 immunohistochemistry (IHC) clones. Methods: AIM-PD-L1-NSCLC was trained using convolutional neural networks to identify and quantify PD-L1-positive cells in digitized whole slide images (WSI) of tissue samples. Models were developed using over 5,000 diverse clinical biopsies and resections, including primary and metastatic adenocarcinoma and squamous cell carcinoma samples collected from 10 clinical trials and from two clinical laboratories, each stained for PD-L1 with one of four IHC clones: SP263 (N=1,320), SP142 (N=1,829) (both Ventana Medical Systems Inc., Tucson, AZ), 28-8 (N=1,331), or 22C3 (N=843) (both Agilent Technologies, Santa Clara, USA). Slides were digitized using Aperio, Philips, and Ventana scanners, and WSI were split into training (N=3,818) and test (N=1,505) datasets. The training dataset was annotated by board certified pathologists (313,770 annotations) to label tissue regions and cells. Human Interpretable features representing the number of tumor cells were automatically extracted from the model and a slide level Tumor Proportion Score (TPS) calculated as the proportion of PD-L1+ cancer cells divided by total cancer cells in tumor regions. Model predicted slide level TPS were compared with the median TPS of five pathologists' scores using intraclass correlation coefficient (ICC) statistics. Results: There was high concordance between ML model-predicted and median pathologists' slide level TPS for all PD-L1 clones (ICC 0.93 (95% CI 0.90-0.94), and for each individual clone: 22C3 ICC 0.93 (95% CI 0.89-0.96); SP142 ICC 0.88 (95% CI 0.79-0.93); SP263 ICC 0.96 (95% CI 0.93-0.97; 28-8 ICC 0.90 (95% CI 0.85-0.93). Conclusions: AIM PD-L1 NSCLC is highly concordant with the gold standard pathologist consensus score across four PD-L1 clones in a large diverse dataset. This model could support patient enrollment and stratification in prospective clinical trials, as well as quality control of staining and pathology drift. Citation Format: Michael Griffin, Mevlana Gemici, Ashar Javed, Nishant Agrawal, Murray Resnick, Limin Yu, Sara Hoffman, Victoria Mountain, Jamie Harisiades, Megan Rothney, Benjamin Glass, Ilan Wapinski, Andrew Beck, Eric Walk. AIM PD-L1-NSCLC: Artificial intelligence-powered PD-L1 quantification for accurate prediction of tumor proportion score in diverse, multi-stain clinical tissue samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 471.

Automated Tumor Proportion Scoring for Assessment of PD-L1 Expression Based on Multi-Stage Ensemble Strategy

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma

PD-L1 Prediction of Lung Cancer by a Radiomics Method Using Rough Tumor Mask in CT Images

Deep Semi Supervised Generative Learning for Automated PD-L1 Tumor Cell Scoring on NSCLC Tissue Needle Biopsies

A New AI-assisted Scoring System for PD-L1 expression in NSCLC

Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer

A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry

Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images

Abstract 471: AIM PD-L1-NSCLC: Artificial intelligence-powered PD-L1 quantification for accurate prediction of tumor proportion score in diverse, multi-stain clinical tissue samples

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC

Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images

Development of Prognostic Biomarkers by TMB-Guided WSI Analysis: A Two-Step Approach

Automatic Scoring Method for Tumor IHC Images Based on Deep Learning and Its Application on P53 Protein.

Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study

Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma

Pan-cancer Computational Histopathology Reveals Tumor Mutational Burden Status Through Weakly-Supervised Deep Learning.

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring

Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

Deep learning-based image analysis predicts PD-L1 status from 18F-FDG PET/CT images in non-small-cell lung cancer